Infliximab Efficacy May Be Linked to Full TNF-α Blockade in Peripheral Compartment-A Double Central-Peripheral Target-Mediated Drug Disposition (TMDD) Model

• Main Authors: David Ternant (Author), Olivier Le Tilly (Author), Laurence Picon (Author), Driffa Moussata (Author), Christophe Passot (Author), Theodora Bejan-Angoulvant (Author), Céline Desvignes (Author), Denis Mulleman (Author), Philippe Goupille (Author), Gilles Paintaud (Author)
• Format: Book
• Published: MDPI AG, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Infliximab is an anti-TNF-α monoclonal antibody approved in chronic inflammatory bowel diseases (IBD). This study aimed at providing an in-depth description of infliximab target-mediated pharmacokinetics in 133 IBD patients treated with 5 mg/kg infliximab at weeks 0, 2, 14, and 22. A two-compartment...